We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

1
Home
Companies

Shattuck Labs

Shattuck Labs
Leadership team

Dr. Taylor H. Schreiber M.D., Ph.D. (Co-Founder, CEO & Director)

Dr. Arundathy Nirmalini Pandite M.B.A., M.D. (Chief Medical Officer)

Ms. Casi DeYoung (Chief Bus. Officer)

Products/ Services
Biopharma, Biotechnology, Life Science
Number of Employees
50 - 100
Headquarters
Austin, Texas, United States
Established
2016
Company Registration
SEC CIK number: 0001680367
Revenue
20M - 100M
Traded as
NASDAQ:STTK
Social Media
URL
https://www.shattucklabs.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
History

Shattuck Labs was co-founded in 2012 by Dr. Jeff Shattuck and Dr. Michael Sussman. Together, they set out to discover novel therapies for diseases which had previously lacked effective treatment options. Over the years, the size of the team and the scope of its research has grown, resulting in the successful launch of several new treatment options and the initiation of multiple clinical trials.

Mission
We are devoted to creating treatments that will improve the lives of patients around the world. We believe that our work has the capacity to significantly address the unmet needs of many individuals who are suffering from incurable diseases.
Vision
Our vision is that cutting-edge therapies developed in Shattuck Labs will serve as the standard of care across an ever-growing landscape of new and improved treatments.
Key Team

Mr. Andrew R. Neill M.B.A. (Chief Financial Officer)

Conor Richardson (Sr. Director of Fin. & Investor Relations)

Dr. Abhinav A. Shukla Ph.D. (Chief Technical Officer)

Ms. Erin Ator Thomson J.D. (Gen. Counsel, Corp. Sec. and Chief Ethics & Compliance Officer)

Ms. Fatima Rangwala M.D., Ph.D. (Sr. VP of Clinical Research)

Dr. Thomas Lampkin Pharm.D. (Sr. VP of Regulatory Affairs)

Recognition and Awards
Shattuck Labs has been recognized with numerous awards over the years, including the National Institutes of Health Pioneer Award, the Lasker Award for Clinical Research Excellence, and the R&D 100 Award for Innovative Biotechnology Product of the Year.
References

https://in.investing.com/equities/shattuck-labs-inc

https://finance.yahoo.com/quote/STTK/profile?p=STTK

https://www.crunchbase.com/organization/shattuck-labs

https://www.shattucklabs.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Shattuck Labs
Leadership team

Dr. Taylor H. Schreiber M.D., Ph.D. (Co-Founder, CEO & Director)

Dr. Arundathy Nirmalini Pandite M.B.A., M.D. (Chief Medical Officer)

Ms. Casi DeYoung (Chief Bus. Officer)

Products/ Services
Biopharma, Biotechnology, Life Science
Number of Employees
50 - 100
Headquarters
Austin, Texas, United States
Established
2016
Company Registration
SEC CIK number: 0001680367
Revenue
20M - 100M
Traded as
NASDAQ:STTK
Social Media
URL
https://www.shattucklabs.com